Compass Pathways reports 52-week follow-up on psilocybin trial

Compass Pathways' 52-week follow-up on psilocybin trial

Compass Pathways has released 52-week follow-up data from its Phase 3 trial, COMP005, evaluating the efficacy of its psilocybin candidate, COMP360, for treatment-resistant depression (TRD). The trial, which included 258 participants, aimed to assess the long-term benefits of the psychedelic compound.

What the study found

The trial, conducted in three parts, initially involved a 6-week blinded phase (Part A) where participants received either a 25 mg dose of COMP360 or a placebo. This was followed by a 20-week blinded segment (Part B) where participants could potentially receive a second dose. In the final 26-week open-label phase (Part C), those who relapsed or did not achieve remission were offered another 25 mg dose of psilocybin.

According to Compass Pathways, approximately 70% of the original participants, or 179 out of 258, entered Part C. The company reported a notable additional benefit from the further dose in Part C, leading to an average 13-point reduction in MADRS scores from baseline at Week 52 among those who received the active dose in Part A.

Why it matters

The findings from Compass Pathways' trial are significant as they suggest that psilocybin could offer sustained benefits for individuals with treatment-resistant depression, a condition that is often challenging to manage with conventional therapies. The reduction in MADRS scores indicates a potential for improved mental health outcomes over a longer period, which is crucial for patients who have not responded to other treatments.

Regulatory context

As interest in psychedelic therapies grows, regulatory bodies are closely monitoring trials like COMP005. The results from Compass Pathways may influence future regulatory decisions and the potential approval of psilocybin-based treatments for depression.

The trial's findings contribute to the expanding body of research on psychedelics, which could pave the way for new therapeutic options for mental health disorders.

"Reporting based on Psychedelic Alpha. Read the original: link.